Catalyst Biosciences Profit Margin

As of the most recent data (June 2026), CBIO shows a profit margin of 421.62%. That compares with 13.75% in the prior-year period — up 2966.8% year over year. That is above the Healthcare sector average of 21.34%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CBIO's profit margin is now 421.62% (was 13.75%) — a 2966.8% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Catalyst Biosciences is outperforming or lagging.

The Healthcare sector average profit margin is about 21.34%. Catalyst Biosciences is at 421.62%, which is higher that average. That is roughly 1876.2% above the sector mean. Use the comparison chart on this page to see how CBIO stacks up against individual peers as well.

That compares with 13.75% in the prior-year period — up 2966.8% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Catalyst Biosciences with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has Catalyst Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently 421.62%) with ownership activity and broader fundamentals.